| Автор | Henry, Veronica |
| Дата выпуска | 1993 |
| Формат | application.pdf |
| Издатель | Taylor & Francis Group |
| Копирайт | Copyright Taylor and Francis Group, LLC |
| Название | 1992 Le Tourneau award: Problems with Pharmaceutical Regulation in the United States |
| Тип | research-article |
| DOI | 10.1080/01947649309510932 |
| Electronic ISSN | 1521-057X |
| Print ISSN | 0194-7648 |
| Журнал | Journal of Legal Medicine |
| Том | 14 |
| Первая страница | 617 |
| Последняя страница | 639 |
| Аффилиация | Henry, Veronica; Associate, Kopff, Nardelli & Dopf |
| Выпуск | 4 |
| Библиографическая ссылка | Dillman. 1991. Prescription Drug Approval and Terminal Diseases: Desperate Times Require Desperate Measures. Vand. L. Rev., 44: 925928 |
| Библиографическая ссылка | Nov. 1992. From Laboratory to Medicine Cabinet Nov., 16 Caring |
| Библиографическая ссылка | Aug. 27 1990. PMA Lines Up with FDA Panel on Drug Reviews: Pharmaceutical Manufacturers Association, Food and Drug Administration,, Chemical Marketing Rep. Aug. 27, 7 |
| Библиографическая ссылка | Allan. 1992. A Primer of Drug Safety Surveillance: An Industry Perspective Part 1: Information Flow, New Drug Development, and Federal Regulations. J. Pharmacy Tech., July/Aug.: 164 |
| Библиографическая ссылка | 1993. FDA's 26 New Molecular Entity Approvals in 1992 Are Fewer than Record 30 NME Clearances in 1991 but Are Improvement Over Agency Performance from 1986–1990. F‐D‐C REPS.—(The Pink Sheet), Jan. 11: 9 |
| Библиографическая ссылка | 1993. New Drugs of 1992. Drug Topics, Feb. 8: 48 |
| Библиографическая ссылка | 1990. Drug Industry Claims FDA Route too Long: FDA Drug Approval Process. Chemical Marketing Rep., Jan. 22: 5 |
| Библиографическая ссылка | Johnson. 1984. Rx for Pharmaceuticals. Penton/IPC, Industry Week, Aug. 6: 32 |
| Библиографическая ссылка | Hayes. 1990. Safety Considerations in Product Development. Drug Safety, 5(Supp. 1): 24 |
| Библиографическая ссылка | Williams and Copelan. 1993. New Drugs for 1993. The Consultant Pharmacist, Mar.: 208 |
| Библиографическая ссылка | 1987. Fed. Reg., 52: 19,466 |
| Библиографическая ссылка | Miller and Young. 1989. The Drug Approval Process at the Food and Drug Administration: New Biotechnology as a Paradigm of a Science‐Based Activist Approach. Arch. Int. Med., 149: 655 |
| Библиографическая ссылка | Ziporyn. 1985. The Food and Drug Administration: How Those Regulations Came to Be. J.A.M.A., 254: 20392041 |
| Библиографическая ссылка | Dunn, C. 1938. Federal Food, Drug and Cosmetic Act, : 88 |
| Библиографическая ссылка | Nelson. 1988. Regulation of Investigational New Drugs: “Giant Step for the Sick and Dying?”. Geo. L.J., 77: 463468 |
| Библиографическая ссылка | Cavers. 1939. The Food, Drug and Cosmetic Act of 1938: Its Legislative History and Its Substantive Provision. Law & Contemp. Probs., 6: 220 |
| Библиографическая ссылка | Farley. 1987. Benefit vs. Risk: How FDA Approves New Drugs. FDA Consumer, Dec.: 10 ‐Jan. 1988, |
| Библиографическая ссылка | Richardson. 1987. The Orphan Drug Tax Credit: An Inadequate Response to an Ill‐Defined Problem. Am. J. Tax Pol'y, 6: 135143 |
| Библиографическая ссылка | Fed. Reg., 5341518 |
| Библиографическая ссылка | Rin‐Laures and Janofsky. 1991. Recent Development Concerning the Orphan Act. Harv. J.L. & Tech., 4: 269271 |
| Библиографическая ссылка | Marwick. 1988. FDA Seeks Swifter Approval of Drugs for Some Life‐Threatening or Debilitating Diseases. J.A.M.A., 260: 2976 |
| Библиографическая ссылка | Young. 1988. The FDA's New Procedures for the Use of Investigational Drugs in Treatment. J.A.M.A., 259: 22672268 |
| Библиографическая ссылка | Delaney. 1989. Patient Access to Experimental Therapy. J.A.M.A., 261: 2444 |
| Библиографическая ссылка | Sage. 1988. Drug Product Liability and Health Care Delivery Systems. Stan. L. Rev., 40: 989 |
| Библиографическая ссылка | Kolata. 1991. Patients Going Underground to Buy Experimental Drugs. N.Y. Times, Nov. 4: 1 |
| Библиографическая ссылка | Cotton. 1991. FDA “Pushing Envelope” on AIDS Drug. J.A.M.A., 266: 757 |
| Библиографическая ссылка | 1991. Regulators Set Faster Approval Process for a New Drug. Reuters Bus. Rep., Nov. 13 |
| Библиографическая ссылка | Gasbarro. 1990. The High Cost of Drugs Is a Bitter Pill to Take. Wash. Times, Dec. 3: M6 |
| Библиографическая ссылка | Waldholz. 1991. During 1980's Prescription Drug Prices Rose Almost 3 Times the Inflation Rate. Wall St. J., Sept. 25: B3 |
| Библиографическая ссылка | Iglehart. 1991. Health Policy Report: The Food and Drug Administration and Its Problems. New Eng. J. Med., 325: 217 |
| Библиографическая ссылка | Ballin. 1982. Regulation and Development of New Drugs. J.A.M.A., 247: 29952996 |
| Библиографическая ссылка | 1990. Panel Recommends Changes to Expedite Approval of Cancer, AIDS Drugs. Am. J. Hosp. Pharmacy, 47 Nov.: 24102411 |
| Библиографическая ссылка | 1990. See PHS Proposes “Parallel Track” for New AIDS Drugs. Pub. Health Rep., 105: 541 |
| Библиографическая ссылка | Nightingale. 1985. The Evolving Drug Approval Process: Challenges and Opportunities. Food, Drug & Cosm. L. J., 40: 499 |
| Библиографическая ссылка | Marwick. 1987. Proposal to Make Investigational New Drugs Available Without Clinical Trial Participation in Certain Cases Is Receiving Mixed Responses. J.A.M.A., 257: 3020 |
| Библиографическая ссылка | Cooper. 1989. Controlled Clinical Trials of AIDS Drugs: The Best Hope. J.A.M.A., 261: 2445 |
| Библиографическая ссылка | Mar. 9 1981. “Hearings Before the Subcommittee on Health and the Environment of the Comm. on Energy and Commerce on Orphan Drug Act”. Mar. 9, 97th Cong., 1st Sess. 49 |
| Библиографическая ссылка | Fed. Reg., 5219,467 |
| Библиографическая ссылка | Merz. 1988. Treatment INDs: Promising, Problematic. J.A.M.A., 259: 16071608 |
| Библиографическая ссылка | Anderson. 1989. Cancer and AIDS Groups Push for Changes in Drug Approval Process. J. Nat'l Cancer Inst., 81: 829 |
| Библиографическая ссылка | Wittes. 1988. Noninvestigational Uses of Investigational Drugs: Some Implications of FDA's Revised Regulations. J. Nat'l Cancer Inst., 80: 301 |
| Библиографическая ссылка | 1992. Prescription Drug User Fee Statute Enacted. J.A.M.A., 268: 3418 |
| Библиографическая ссылка | Conlan. 1993. Drug Industry R & D Spending Continues to Climb, PMA Reports. Drug Topics, Feb. 8: 96 |
| Библиографическая ссылка | 1992. New Drug Law to Speed Scientific Review. Nature, Oct. 15: 563 |
| Библиографическая ссылка | 1993. User Fee Invoices Will Go Out to Companies “Two Weeks” After President Signs Supplemental Appropriations Bill Authorizing Fee Collection, FDA's Veverka Says. F‐D‐C Rep. (The Pink Sheet), July 5: 5 |
| Библиографическая ссылка | 1992. Changes in FDA Drug Classification and Priority Review Policy. Am. J. Hosp. Pharmacy, 49 Oct.: 2386 |
| Библиографическая ссылка | Nov. 13 1991. Administration Acts to Speed Drug Approval,, Nov. 13, UPI. |
| Библиографическая ссылка | 1992. Clinical Briefs: Approval for Broader Use of DDI. Am. Fam. Physician, 46 Dec.: 1841 |
| Библиографическая ссылка | 1991. Rushing DDI to Market. Time, Oct. 21: 83 |
| Библиографическая ссылка | 1992. Speeding Drug Ok's: Quayle's Plan for Accelerating Approvals by 40% Is Implemented by New Regulations. Am. Druggist, June: 12 |
| Библиографическая ссылка | Gupta. 1991. Venture Capital Funds Are Expected to Rise Sharply. Wall St. J., Nov. 27: B2 |
| Библиографическая ссылка | Gatty. 1993. Whatever Happened to User Fees and the FDA's Promise to Expedite New Drug Approvals?. Hosp. Formul., July: 656 |
| Библиографическая ссылка | McKercher. 1992. Issues in Health Policy: Pharmaceutical Research and Development. Clinical Therapeutics, Sept./Oct.: 762 |
| Библиографическая ссылка | Batterman. 1990. Brother Can You Spare a Drug: Should the Experimental Drug Distribution Standards Be Modified in Response to the Needs of Persons with AIDS?. Hofstra L. Rev., 19: 191219 |
| Библиографическая ссылка | Grossman. 1984. The Orphan Drug Act: Adoption or Foster Care?. Food, Drug & Cosm. L.J., 39: 128 |
| Библиографическая ссылка | Finkel. 1984. The Orphan Drug Act and the Federal Government's Orphan Products. Pub. Health Rep., 99 May/June: 313 |
| Библиографическая ссылка | Asbury. 1991. The Orphan Drug Act: The First 7 Years. J.A.M.A., 265: 893 |
| Библиографическая ссылка | Carter and Bennet. 1989. Developments in Orphan Drugs. Food, Drug & Cosm. L.J., 44: 627 |
| Библиографическая ссылка | June 26 1980. “Hearing Before the Subcomm. on Health and the Environment of the Comm. on Interstate and Foreign Commerce: Drug Regulation Reform‐Oversight (Orphan Drugs)”. June 26, 96th Cong., 2d Sess. |
| Библиографическая ссылка | 1992. Orphan Drugs: The PMA's Latest Survey Shows an Increase in the Development of Drugs for Rare Disorders. Am. Druggist, June: 12 |
| Библиографическая ссылка | Shulman, Bienz‐Tadmor, Seo, DiMasi and Lasagna. 1992. Implementation of the Orphan Drug Act: 1983–1991. Food, Drug & Cosm. L.J., 47: 363365 |
| Библиографическая ссылка | Carey and Hamilton. 1990. These “Orphans” Don't Need Any Nurturing. Bus. Week, July 2: 38 |
| Библиографическая ссылка | 1991. 1991 Annual Survey: 176 Medicines in Testing for Rare Diseases. Orphan Drugs, : 1 |
| Библиографическая ссылка | Fed. Reg., 563338 |
| Библиографическая ссылка | Lawton. 1991. Controversy Under the Orphan Drug Act: Is Resolution on the Way?. Food, Drug & Cosm. L.J., 46: 327328–32. |
| Библиографическая ссылка | 1991. Fed. Reg., 56: 33383346 |
| Библиографическая ссылка | Kenney. 1989. The Orphan Drug Act: Is It a Barrier to Innovation? Does It Create Unintended Windfalls?. Food, Drug & Cosm. L.J., 43: 627628 |
| Библиографическая ссылка | Thomas. 1990. Re‐assessing the Orphan Drug Act. Colum. J.L. & Soc. Probs., 23: 413433 |
| Библиографическая ссылка | 1991. Fed. Reg., 56: 33383346 |
| Библиографическая ссылка | 1991. Fed. Reg., 56: 33383345 |
| Библиографическая ссылка | 1991. Fed. Reg., 56: 33383345 |
| Библиографическая ссылка | Feb. 7 1990. “Hearings Before the House Subcomm. on Health and the Environment”. Feb. 7, 101st Cong., 2d Sess. |
| Библиографическая ссылка | Chapman. 1990. Thalidomide Isn't the Only Risk in Drug Regulation. Chi. Trib., June 3: 3 |
